Fresenius Kabi Chile Ltda. Pharmaceutical Import Profile — Chile (DGFT 2022–2026)

Name: Fresenius Kabi Chile Ltda. Pharmaceutical Import Records from India — 2 Products, $900.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Chile Ltda. — Pharmaceutical Importer Profile (2026) | 2 Products, $900.0K Trade | TransData Nexus

Fresenius Kabi Chile Ltda.

Pharmaceutical Importer · Chile · Oncology Focus · $900.0K Total Trade · DGFT Verified

Fresenius Kabi Chile Ltda. is a pharmaceutical importer based in Chile with a total trade value of $900.0K across 2 products in 2 therapeutic categories. Based on 18 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi Chile Ltda. sources from 1 verified Indian supplier, with Fresenius Kabi Oncology Limited accounting for 100.0% of imports.

Fresenius Kabi Chile Ltda. — Import Portfolio & Supplier Network

Fresenius Kabi Chile Ltda. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Chile Ltda.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$2.5M	85	100.0%

Fresenius Kabi Chile Ltda. sources from 1 verified Indian supplier across 74 distinct formulations. The sourcing is highly concentrated — Fresenius Kabi Oncology Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Docetaxel INJ. 120MG/6ML vial batch no.	$100.0K	2
Oxaliplatino injection 100MG/20ML vial	$100.0K	2
Carboplatino injection 450MG/45ML vial	$100.0K	2
Gemcitabina INJ. 1GM/26.3ML vial b/n: 87230486ba md:11/23	$100.0K	2
Paclitaxel INJ. 300MG/50ML vial batch	$96.9K	2
Doxorubicina (doxorubicin) hcl INJ. 50MG/25ML vial batch no. 87250066aa, mfg. dt. 03/2025, exp. dt.	$59.8K	2
Docetaxel INJ.80MG/4ML	$50.0K	1
Docetaxel injection 120MG/6ML vial	$50.0K	1
Paclitaxel INJ. 300MG/50ML batch no.	$50.0K	1
Gemcitabina (gemcitabine) INJ.	$50.0K	1
Oxaliplatino INJ. 100MG/20ML vial	$50.0K	1
Carboplatino INJ. 450MG/45ML vial b/n: 87230472ba md:11/23	$50.0K	1
Carboplatino(carboplatin) INJ. 450MG/45ML vial (batch no. 87240523ab mfg. dt. 12/2024 exp. dt. 11/2026)	$50.0K	1
Citarabina INJ. 1GM/10ML vial batch no.87240072aa, mfg. dt. 02/2024, exp. dt.	$50.0K	1
Carboplatino INJ. 450MG/45ML vial batchno. 87240039aa, mfg. dt. 01/2024, exp.dt.	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Docetaxel	Oncology	$500.0K	10	1.3%	11
2	Oxaliplatin	Advanced Oncology	$400.0K	8	0.9%	15

Fresenius Kabi Chile Ltda. imports 2 pharmaceutical products across 2 categories into Chile totaling $900.0K.

Fresenius Kabi Chile Ltda. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Chile Ltda. is a subsidiary of the global healthcare company Fresenius Kabi, specializing in essential medicines and technologies for infusion, transfusion, and clinical nutrition. Established in 1999, Fresenius Kabi has become a key player in the Latin American pharmaceutical market, offering a comprehensive range of products and services for hospitals and home care.

Headquartered in Santiago, Chile, Fresenius Kabi Chile Ltda. operates as a pharmaceutical importer and distributor, focusing on providing critical care solutions to the Chilean healthcare system. The company plays a significant role in the distribution of intravenous (IV) generic drugs, including oncology treatments, to hospitals and healthcare facilities across the country.

2Distribution Network

Fresenius Kabi Chile Ltda. maintains a robust distribution network to ensure the timely delivery of its products throughout Chile. The company's primary distribution center is located in Santiago, which serves as the central hub for logistics operations. From this facility, products are dispatched to various regions within Chile, ensuring nationwide coverage. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive operations in Santiago suggest a well-established infrastructure capable of supporting its distribution needs.

3Industry Role

In Chile's pharmaceutical supply chain, Fresenius Kabi Chile Ltda. functions as a pharmaceutical importer and distributor, focusing on the importation and distribution of finished pharmaceutical formulations. The company's product portfolio includes a range of intravenous generic drugs, such as oncology treatments, which are supplied to hospitals and healthcare facilities across the country. By importing and distributing these essential medicines, Fresenius Kabi Chile Ltda. plays a crucial role in ensuring the availability of critical care solutions within the Chilean healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Chile Ltda.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Chile Ltda. demonstrates a high level of sourcing concentration, with a total import value of $900,000 USD from India across 18 shipments. The company's imports are concentrated in two therapeutic categories: Oncology (55.6%) and Advanced Oncology (44.4%). The top five products imported include Docetaxel ($500,000, Rank #11, 1.3% share) and Oxaliplatin ($400,000, Rank #15, 0.9% share). Notably, the company's entire portfolio is concentrated in these five products, indicating a strategic focus on specific oncology treatments.

This sourcing strategy suggests a deliberate approach to concentrate on high-demand oncology medications, potentially leveraging supplier relationships to secure favorable terms and ensure a consistent supply of these critical drugs. However, the lack of diversification in the product portfolio may expose the company to risks associated with supply chain disruptions or changes in market demand for these specific products.

2Supply Chain Resilience

Fresenius Kabi Chile Ltda.'s supply chain resilience is closely tied to its sourcing strategy, which relies heavily on a single supplier, Fresenius Kabi Oncology Limited, accounting for 100% of the company's imports from India. This single-source dependency may pose risks related to supply chain disruptions, such as production delays, quality issues, or geopolitical factors affecting trade relations.

Importing Pharmaceuticals into Chile — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Chile

1Regulatory Authority & Framework

In Chile, the primary regulatory authority overseeing pharmaceutical imports and marketing is the Public Health Institute (Instituto de Salud Pública, ISP). The ISP is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Chilean market.

Key legislation governing pharmaceutical imports includes the Health Code (Código Sanitario) and the Pharmaceutical Regulations (Reglamento Sanitario de los Alimentos). These regulations outline the requirements for importing, registering, and marketing pharmaceutical products in Chile. The marketing authorization pathway for Indian generics involves obtaining approval from the ISP, which includes submitting comprehensive documentation on product quality, safety, and efficacy.

2Import Licensing & GMP

Import licensing requirements in Chile stipulate that pharmaceutical importers must obtain authorization from the ISP before bringing products into the country. This process involves submitting detailed information about the products, including manufacturing processes, quality control measures, and compliance with Good Manufacturing Practice (GMP) standards.

GMP certificates recognized by the ISP include those issued by reputable authorities such as the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Fresenius Kabi Chile Ltda. must ensure that their manufacturing facilities hold valid GMP certifications from these recognized bodies to meet regulatory requirements.

Fresenius Kabi Chile Ltda. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Chile Ltda.'s product strategy focuses on oncology treatments, particularly intravenous generic drugs such as Docetaxel and Oxaliplatin. This focus aligns with the company's commitment to providing essential medicines for critically ill patients, addressing the significant demand for cancer therapies in Chile.

The market demand for these products is driven by the high prevalence of cancer in the region and the need for affordable, effective treatment options. By concentrating on these therapeutic areas, Fresenius Kabi Chile Ltda. aims to meet the critical needs of the healthcare system and improve patient outcomes.

2Sourcing Profile

Fresenius Kabi Chile Ltda. employs a sourcing strategy that emphasizes the importation of generic drugs, particularly in the oncology sector. The company imports finished pharmaceutical formulations from India, focusing on a select range of products to maintain a streamlined and efficient supply chain.

India's role in this sourcing strategy is pivotal, as it provides high-quality generic formulations that meet international standards. By importing these products, Fresenius Kabi Chile Ltda. can offer cost-effective treatment options to the Chilean market while ensuring the availability of essential medicines.

3Market Positioning

Seller's Guide — How to Become a Supplier to Fresenius Kabi Chile Ltda.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Chilean market by partnering with Fresenius Kabi Chile Ltda. The company's concentrated sourcing strategy indicates a potential openness to expanding its supplier base, provided that new suppliers can meet the stringent quality standards and regulatory requirements set by the ISP.

Gaps in Fresenius Kabi Chile Ltda.'s current sourcing include a limited diversification of product formulations and a reliance on a single supplier. New Indian suppliers offering a broader range of oncology treatments or alternative formulations may find opportunities to collaborate with the company, thereby enhancing its product portfolio and supply chain resilience.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Fresenius Kabi Chile Ltda.

What products does Fresenius Kabi Chile Ltda. import from India?

Fresenius Kabi Chile Ltda. imports 2 pharmaceutical products across 2 categories. Top imports: Docetaxel ($500.0K), Oxaliplatin ($400.0K).

Who supplies pharmaceuticals to Fresenius Kabi Chile Ltda. from India?

Fresenius Kabi Chile Ltda. sources from 1 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (100.0% of imports, $2.5M).

What is Fresenius Kabi Chile Ltda.'s total pharmaceutical import value?

Fresenius Kabi Chile Ltda.'s total pharmaceutical import value from India is $900.0K, based on 18 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Chile Ltda. focus on?

Fresenius Kabi Chile Ltda. imports across 2 categories. The largest: Oncology (55.6%), Advanced Oncology (44.4%).

Get Full Fresenius Kabi Chile Ltda. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.